Management of Thyroid Disease in Pregnancy

Rationale for Current Management

• The American Academy of Family Physicians recommends methimazole as the preferred antithyroid medication in the second and third trimesters, due to its lower teratogenic risk during organogenesis 1, 2
• The treatment goal is to maintain free T4 or free thyroxine index (FTI) in the high-normal range using the lowest possible thioamide dosage, with a therapeutic target of a subclinical hyperthyroid state during pregnancy 1, 2

Key Monitoring Strategy

• Regular thyroid function monitoring is necessary, with checks of free T4 or FTI every 2-4 weeks to guide any necessary dosage adjustments 1, 2
• Monitoring for symptoms of agranulocytosis, such as sore throat and fever, is also crucial, requiring immediate discontinuation and complete blood count 2

Critical Third Trimester Considerations

• The American Academy of Family Physicians recommends informing the newborn's physician about maternal Graves' disease due to the risk of neonatal thyroid dysfunction 1, 2
• Monitoring the mother for normal heart rate and appropriate fetal growth is also necessary 2
• Transient suppression of fetal/neonatal thyroid function can occur with thioamide therapy, but usually resolves without treatment 2

Postpartum Planning

• Breastfeeding is safe with methimazole at a dose of 5mg 2
• Continue monitoring thyroid function postpartum, with potential need for dose adjustment 2